Equillium Inc Total Assets
Equillium Inc total assets. Based on the latest financial reports, Equillium Inc (EQ) holds total assets worth $58.67 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Equillium Inc (EQ) market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Equillium Inc (2017–2025)
Total assets of Equillium Inc from 2017 to 2025. This chart illustrates how Equillium Inc's total assets have evolved over time, based on quarterly financial data. See Equillium Inc stock price for real-time trading data and today's change.
Equillium Inc - Asset Composition Analysis
Equillium Inc Total Assets Breakdown (December 2025)
Equillium Inc total assets breakdown as of December 2025. Equillium Inc's total assets of $58.67 Million consist of 95.0% current assets and 5.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 95.0% |
| Accounts Receivable | $108.00K | 0.3% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2017–2025)
This chart illustrates how Equillium Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore EQ working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Equillium Inc's current assets represent 95.0% of total assets in 2025, a decrease from 100.0% in 2017.
- Cash Position: Cash and equivalents constituted 95.0% of total assets in 2025, down from 99.3% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 0.3% of total assets.
Equillium Inc Competitors by Total Assets
Key competitors of Equillium Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Equillium Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 23.40 | 1.65 | 11.85 |
| Quick Ratio | 23.40 | 1.65 | 11.85 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $55.50 Million | $4.72 Million | $84.39 Million |
Equillium Inc - Advanced Valuation Insights
This section examines the relationship between Equillium Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.18 |
| Latest Market Cap to Assets Ratio | 2.80 |
| Asset Growth Rate (YoY) | 24.5% |
| Total Assets | $31.89 Million |
| Market Capitalization | $89.41 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Equillium Inc's assets at a significant premium (2.80x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Equillium Inc's assets grew by 24.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Equillium Inc (2017–2025)
The table below shows the annual total assets of Equillium Inc from 2017 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $31.89 Million | +24.54% |
| 2024-12-31 | $25.60 Million | -49.33% |
| 2023-12-31 | $50.53 Million | -35.57% |
| 2022-12-31 | $78.42 Million | -8.18% |
| 2021-12-31 | $85.41 Million | -0.03% |
| 2020-12-31 | $85.43 Million | +53.82% |
| 2019-12-31 | $55.54 Million | -17.31% |
| 2018-12-31 | $67.16 Million | +839.15% |
| 2017-12-31 | $7.15 Million | -- |
About Equillium Inc
Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases. It also develops EQ302, a bi-specific inhibitor of IL-15 and IL-21 fo… Read more